Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cordlife GroupCLIFF 40 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates CLIFF with a GF Score™ of 40/100 and a GF Value™ of $0.16. The stock has 4 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Cordlife Group ranks worse than 598801.8% on this metric.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cordlife Group was 51.80% per year. The lowest was -54.90% per year. And the median was -10.40% per year.
Cordlife Group (OTCPK:CLIFF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cordlife Group 3-Year EBITDA Growth Rate Related Terms
CLIFF vs TMO, DHR, NTRA: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Cordlife Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cordlife Group's 3-Year EBITDA Growth Rate falls into.
Cordlife Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Cordlife Group (CLIFF) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cordlife Group and its competitors. According to the industry distribution chart, Cordlife Group ranks #999999 out of 167 companies in the Medical Diagnostics & Research industry.
Is Cordlife Group's 3-Year EBITDA Growth Rate too high?
Cordlife Group's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Cordlife Group ranks #999999 out of 167 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Cordlife Group has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #999999 out of 167 companies for 3-Year EBITDA Growth Rate. This places Cordlife Group in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.60, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Cordlife Group (CLIFF) has a current 3-Year EBITDA Growth Rate of 0.00%. The stock's GF Value™ is $0.16, compared to a current price of $0.15 — trading 6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Cordlife Group's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued.
The current stock price of $0.15 is trading 6% below its estimated GF Value™ of $0.16.
Key valuation signals for CLIFF:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: $0.16 vs. price of $0.15 (6% below fair value)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a Singapore-based consumer healthcare company focused on cord blood and tissue banking and related diagnostics for families. Its core business is the collection, processing, testing, and cryogenic storage of umbilical cord blood and cord tissue stem cells, sold largely through annual or multi-year storage contracts to parents in Asia. The group also provides diagnostics and screening services, including prenatal and newborn testing, through its diagnostics operations. Its main markets are Singapore, Hong Kong, Malaysia, Indonesia, India, the Philippines, and other parts of Southeast Asia, with Hong Kong and Singapore among its largest revenue contributors. Revenue comes primarily from cord blood banking fees, including initial processing charges and recurring annual storage fees, supplemented by diagnostics testing income. The company operates laboratories and storage facilities in its key markets and markets its services directly to expectant parents, hospitals, and healthcare professionals.
40GF Score
Get the complete analysis for CLIFF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
